BR9909313A - Sistema terapêutico transdérmico, processo para a preparação de um sistema terapêutico transdérmico, e, produto - Google Patents

Sistema terapêutico transdérmico, processo para a preparação de um sistema terapêutico transdérmico, e, produto

Info

Publication number
BR9909313A
BR9909313A BR9909313-8A BR9909313A BR9909313A BR 9909313 A BR9909313 A BR 9909313A BR 9909313 A BR9909313 A BR 9909313A BR 9909313 A BR9909313 A BR 9909313A
Authority
BR
Brazil
Prior art keywords
transdermal therapeutic
therapeutic system
preparation
product
matrix
Prior art date
Application number
BR9909313-8A
Other languages
English (en)
Other versions
BR9909313B1 (pt
BRPI9909313B8 (pt
Inventor
Walter Mueller
James V Peck
Original Assignee
Lohmann Therapie Syst Lts
Discovery Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7862904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9909313(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts, Discovery Therapeutics Inc filed Critical Lohmann Therapie Syst Lts
Publication of BR9909313A publication Critical patent/BR9909313A/pt
Publication of BR9909313B1 publication Critical patent/BR9909313B1/pt
Publication of BRPI9909313B8 publication Critical patent/BRPI9909313B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"SISTEMA TERAPêUTICO TRANSDéRMICO, PROCESSO PARA A PREPARAçãO DE UM SISTEMA TERAPêUTICO TRANSDéRMICO, E, PRODUTO". Um sistema terapêutico transdérmico com uma camada posterior inerte relativamente às substâncias contidas na matriz, uma camada de matriz autoadesiva apresentando uma quantidade eficaz de (-)-5,6,7,8-tetraidro-6-[propil[2-(2-tienil)etilamino)-1-naftol, e uma lâmina de proteção a ser removida antes do uso, caracterizado por uma matriz à base de um sistema de adesivo de polímero não-aquoso à base de acrilato ou silicone com uma solubilidade para (-)-5,6,7,8-tetraidro-6-[propil[2-(2-tienil)etil]-amino)-1-naftol de <242>5 % g/g, essencialmente livre de partículas inorgânicas de silicato.
BRPI9909313A 1998-03-30 1999-03-18 sistema terapêutico transdérmico, processo para a preparação de um sistema terapêutico transdérmico, e, produto BRPI9909313B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814084A DE19814084B4 (de) 1998-03-30 1998-03-30 D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
PCT/EP1999/001795 WO1999049852A1 (de) 1998-03-30 1999-03-18 D2-agonist enthaltendes transdermales therapeutisches system zur behandlung des parkinson-syndroms und verfahren zu seiner herstellung

Publications (3)

Publication Number Publication Date
BR9909313A true BR9909313A (pt) 2000-11-21
BR9909313B1 BR9909313B1 (pt) 2013-11-12
BRPI9909313B8 BRPI9909313B8 (pt) 2021-05-25

Family

ID=7862904

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9909313A BRPI9909313B8 (pt) 1998-03-30 1999-03-18 sistema terapêutico transdérmico, processo para a preparação de um sistema terapêutico transdérmico, e, produto

Country Status (31)

Country Link
US (4) US6884434B1 (pt)
EP (1) EP1033978B1 (pt)
JP (1) JP3984785B2 (pt)
KR (1) KR100432276B1 (pt)
CN (1) CN1142773C (pt)
AR (1) AR014778A1 (pt)
AT (1) ATE210973T1 (pt)
AU (1) AU746856B2 (pt)
BR (1) BRPI9909313B8 (pt)
CA (1) CA2326630C (pt)
CZ (1) CZ297889B6 (pt)
DE (4) DE19814084B4 (pt)
DK (1) DK1033978T3 (pt)
ES (1) ES2170573T3 (pt)
FR (1) FR06C0025I2 (pt)
HK (1) HK1031196A1 (pt)
HU (1) HU226733B1 (pt)
ID (1) ID26646A (pt)
IL (1) IL138722A (pt)
LU (1) LU91269I2 (pt)
MY (1) MY119660A (pt)
NL (1) NL300236I2 (pt)
NO (3) NO325766B1 (pt)
NZ (1) NZ507066A (pt)
PL (1) PL193074B1 (pt)
PT (1) PT1033978E (pt)
SK (1) SK284618B6 (pt)
TR (1) TR200002829T2 (pt)
TW (1) TW579299B (pt)
WO (1) WO1999049852A1 (pt)
ZA (1) ZA200005261B (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
NZ515953A (en) 1999-07-02 2003-06-30 Lts Lohmann Therapie System Ag Microreservoir system on the basis of polysiloxanes and ambiphilic solvents
DK1233763T3 (da) * 1999-11-29 2003-10-20 Lohmann Therapie Syst Lts Transdermale terapeutiske systemer med forbedret stabilitet og en fremgangsmåde til deres fremstilling
DE10054713C2 (de) * 1999-11-29 2002-07-18 Lohmann Therapie Syst Lts Transdermale Therapeutische Systeme mit verbesserter Stabilität und ein Verfahren zu ihrer Herstellung
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AU2005242160B2 (en) * 2000-10-12 2009-02-26 Lts Lohmann Therapie-Systeme Ag Improved transdermal therapeutic system for the treatment of parkinson's disease
EP1344522A1 (en) * 2001-05-08 2003-09-17 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
SI1256340T1 (en) * 2001-05-08 2003-12-31 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10159745A1 (de) 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1426049B1 (en) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
ES2274424T3 (es) * 2003-02-07 2007-05-16 Lts Lohmann Therapie-Systeme Ag Sistema terapeutico transdermico, apropiado para la aplicacion de calor con el fin de acelerar la permeacion de sustancias activas, y su utilizacion.
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1796610A4 (en) * 2004-09-29 2012-12-05 Schwarz Pharma Inc TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON DISEASE
JP5025998B2 (ja) * 2005-06-06 2012-09-12 日東電工株式会社 経皮吸収製剤
CA2548864C (en) 2005-06-06 2012-12-11 Nitto Denko Corporation Percutaneous absorption-type pharmaceutical preparation
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
DE102006028987A1 (de) * 2006-06-24 2007-12-27 Lts Lohmann Therapie-Systeme Ag Ultraschallverstärktes transdermales therapeutisches System
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CN101147739B (zh) * 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
WO2009063171A1 (en) * 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Novel rotigotine salts
HUE027647T2 (en) 2007-11-28 2016-10-28 Ucb Pharma Gmbh Polymorphic form of Rotigotine
EP2255802B1 (en) 2008-02-27 2018-01-17 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
JP6054013B2 (ja) * 2008-02-27 2016-12-27 久光製薬株式会社 貼付製剤
DE102008013701A1 (de) * 2008-03-11 2009-09-17 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit stabilisierter Membran
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
US20110151001A1 (en) * 2008-05-15 2011-06-23 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for external application containing prochlorperazine
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) * 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EP2490673A2 (en) * 2009-10-19 2012-08-29 Actavis Group Ptc Ehf Amorphous rotigotine co-precipitates
KR20160055971A (ko) 2009-12-22 2016-05-18 유씨비 파르마 게엠베하 비결정질형 로티고틴의 고체 분산체의 안정화를 위한 폴리비닐피롤리돈
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
EP2457565A1 (de) 2010-11-29 2012-05-30 Ratiopharm GmbH Transdermales therapeutisches System enthaltend Rotigotin
WO2012074988A1 (en) 2010-12-02 2012-06-07 Ratiopharm Gmbh Rotigotine ionic liquid
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
WO2013020527A1 (en) 2011-08-11 2013-02-14 University Of Veterinary And Pharmaceutical Sciences Brno Faculty Of Pharmacy Utilization of alaptide as transdermal penetration modifier in pharmaceutical compositions for human and veterinary applications containing anti-inflammatory drugs and/or antimicrobial chemotherapeutics
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
CN102499906B (zh) * 2011-10-12 2013-04-17 长春健欣生物医药科技开发有限公司 一种罗替戈汀盐酸盐或自由碱成膜凝胶制剂及其制备方法
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
DE102012205493A1 (de) * 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
AU2013285733B2 (en) 2012-07-05 2016-11-10 Sk Chemicals Co., Ltd. Transdermally absorbable preparation containing rotigotine
WO2014007597A1 (ko) 2012-07-06 2014-01-09 에스케이케미칼(주) 로티고틴 함유 경피흡수제제
TW201431570A (zh) * 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
EP3288957A4 (en) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
CN109806243B (zh) * 2017-11-20 2022-07-15 北京泰德制药股份有限公司 一种含有氟吡汀或其药用盐的皮肤外用贴剂
KR102363218B1 (ko) 2017-12-19 2022-02-14 히사미쓰 세이야꾸 가부시키가이샤 로티고틴 함유 첩부제
TW202016088A (zh) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
EP3584244A1 (en) 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
KR20200046461A (ko) 2018-10-24 2020-05-07 에스케이케미칼 주식회사 비결정 로티고틴 함유 조성물 및 이의 제조 방법
CN113453676A (zh) 2019-02-15 2021-09-28 久光制药株式会社 罗替戈汀稳定化方法
WO2020250840A1 (ja) 2019-06-14 2020-12-17 久光製薬株式会社 ロチゴチン含有貼付剤
WO2020254289A1 (en) 2019-06-17 2020-12-24 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
PT3854388T (pt) 2020-01-24 2023-12-11 Luye Pharma Switzerland Ag Sistema terapêutico transdérmico com o princípio ativo rotigotina e pelo menos um adesivo de silicone não resistente a aminas
CN113368083A (zh) * 2021-06-16 2021-09-10 华健医疗(深圳)有限公司 一种大麻二酚cbd透皮给药系统

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US5268385A (en) 1983-01-03 1993-12-07 Whitby Research, Inc. Method for treating schizophrenia
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5273757A (en) * 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems
DE3827561C1 (pt) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
EP0387751B1 (en) * 1989-03-15 1994-06-08 Nitto Denko Corporation Medicated plasters
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648131B1 (fr) * 1989-06-13 1991-10-18 Oreal Nouveaux derives de tetrahydro -5,6,7,8 naphtalenol-1, leur procede de preparation et leur utilisation en tant qu'agents antioxydants dans des compositions cosmetiques et pharmaceutiques les contenant
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) * 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
JPH06510290A (ja) * 1991-08-27 1994-11-17 シグナス，インコーポレイテッド プラゾシンを投与するための経皮処方物
WO1993007842A1 (en) 1991-10-15 1993-04-29 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
WO1993014727A1 (en) 1992-01-31 1993-08-05 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
EP0656771A4 (en) 1992-08-25 1996-07-31 Cygnus Therapeutic Systems DEVICE FOR TRANSDERMAL DRUG DELIVERY.
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
DE4301781C2 (de) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
CA2166191A1 (en) 1993-06-24 1995-01-05 Dan W. Connors Transdermal delivery system package
EP0707465A4 (en) 1993-07-08 1997-04-16 Cygnus Therapeutic Systems MONOLITHIC MATRIX TRANSDERMAL DELIVERY SYSTEM
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
WO1995005137A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Transdermal delivery system using a combination of permeation enhancers
WO1995005138A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
DE69527408T2 (de) 1994-03-11 2003-02-20 Koninkl Philips Electronics Nv Übertragungssystem für quasiperiodische signale
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
WO1996000110A1 (en) 1994-06-24 1996-01-04 Cygnus, Inc. Iontophoretic sampling device and method
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
WO1996022084A2 (en) 1995-01-19 1996-07-25 Cygnus, Inc. Polymer adhesive formulation containing sorbent particles
WO1996022083A1 (en) 1995-01-19 1996-07-25 Cygnus, Inc. POLYISOBUTYLENE ADHESIVES CONTAINING HIGH Tg TACKIFIER FOR TRANSDERMAL DEVICES
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
IL122432A (en) * 1995-06-07 2000-07-16 Cygnus Therapeutic Systems Transdermal patch for preventing ovulation
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
WO1997009971A2 (en) 1995-09-14 1997-03-20 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
US5843472A (en) * 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
CA2329411C (en) * 1998-05-13 2004-01-27 Cygnus, Inc. Collection assemblies for transdermal sampling system
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
US6398562B1 (en) * 1998-09-17 2002-06-04 Cygnus, Inc. Device and methods for the application of mechanical force to a gel/sensor assembly
FR2792529B1 (fr) 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
KR100317533B1 (ko) * 1999-11-10 2001-12-24 윤종용 반도체 집적회로 장치에서의 레이저 퓨즈박스의 구조 및그에 따른 제조 방법
AU1613101A (en) * 1999-11-23 2001-06-04 Aderis Pharmaceuticals, Inc. Improved process for preparing nitrogen-substituted aminotetralins
DK1233763T3 (da) * 1999-11-29 2003-10-20 Lohmann Therapie Syst Lts Transdermale terapeutiske systemer med forbedret stabilitet og en fremgangsmåde til deres fremstilling
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
DE10018467A1 (de) 2000-04-14 2001-10-25 Bosch Gmbh Robert Elektrische Maschine
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
WO2004000263A1 (en) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1426049B1 (en) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
US7379762B2 (en) 2003-09-04 2008-05-27 Creative Technology Ltd. Portable digital device orientation
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
HUE027647T2 (en) 2007-11-28 2016-10-28 Ucb Pharma Gmbh Polymorphic form of Rotigotine
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
KR20160055971A (ko) 2009-12-22 2016-05-18 유씨비 파르마 게엠베하 비결정질형 로티고틴의 고체 분산체의 안정화를 위한 폴리비닐피롤리돈

Also Published As

Publication number Publication date
EP1033978A1 (de) 2000-09-13
DE59900581D1 (de) 2002-01-31
US10251844B2 (en) 2019-04-09
FR06C0025I1 (pt) 2007-04-27
EP1033978B1 (de) 2001-12-19
AU746856B2 (en) 2002-05-02
DE19814084A1 (de) 1999-10-14
LU91269I9 (pt) 2018-12-31
US7413747B2 (en) 2008-08-19
US6884434B1 (en) 2005-04-26
CN1142773C (zh) 2004-03-24
MY119660A (en) 2005-06-30
HUP0101519A2 (hu) 2001-09-28
ID26646A (id) 2001-01-25
DE122006000035I2 (de) 2009-05-20
CA2326630A1 (en) 1999-10-07
HU226733B1 (en) 2009-08-28
KR100432276B1 (ko) 2004-05-20
TR200002829T2 (tr) 2001-01-22
KR20010042336A (ko) 2001-05-25
DE19814084B4 (de) 2005-12-22
AU2934199A (en) 1999-10-18
BR9909313B1 (pt) 2013-11-12
SK14462000A3 (sk) 2001-04-09
LU91269I2 (fr) 2006-09-26
PT1033978E (pt) 2002-06-28
NO20004915D0 (no) 2000-09-29
SK284618B6 (sk) 2005-07-01
NZ507066A (en) 2003-01-31
TW579299B (en) 2004-03-11
JP3984785B2 (ja) 2007-10-03
CN1295470A (zh) 2001-05-16
FR06C0025I2 (pt) 2007-05-25
PL193074B1 (pl) 2007-01-31
US20050033065A1 (en) 2005-02-10
HK1031196A1 (en) 2001-06-08
AR014778A1 (es) 2001-03-28
NL300236I2 (nl) 2006-12-01
NL300236I1 (nl) 2006-10-02
US20080050424A1 (en) 2008-02-28
JP2002509878A (ja) 2002-04-02
IL138722A (en) 2005-11-20
ZA200005261B (en) 2001-05-22
NO20004915L (no) 2000-11-08
PL343255A1 (en) 2001-07-30
US10322093B2 (en) 2019-06-18
HUP0101519A3 (en) 2002-10-28
NO2008014I2 (no) 2010-04-19
BRPI9909313B8 (pt) 2021-05-25
NO325766B1 (no) 2008-07-14
ATE210973T1 (de) 2002-01-15
IL138722A0 (en) 2001-10-31
NO2008014I1 (no) 2008-11-03
DE122006000035I1 (de) 2006-11-23
AU746856C (en) 1999-10-18
WO1999049852A1 (de) 1999-10-07
CZ20003581A3 (en) 2001-05-16
CZ297889B6 (cs) 2007-04-25
DK1033978T3 (da) 2002-04-15
NO20080489L (no) 2000-08-11
US20080138389A1 (en) 2008-06-12
ES2170573T3 (es) 2002-08-01
CA2326630C (en) 2006-12-05

Similar Documents

Publication Publication Date Title
BR9909313A (pt) Sistema terapêutico transdérmico, processo para a preparação de um sistema terapêutico transdérmico, e, produto
BR0206410A (pt) Artigo com indicação de violação para fixação a uma superfìcie de um substrato, substrato, e, uso de um artigo
PT1009393E (pt) Sistema terapeutico transdermico com camada auto-adesiva tipo reservatorio e camada posterior unidireccionalmente elastica
BR0311437A (pt) Tts de fusão a quente para a administração de rotigotina
BR9205658A (pt) Marcador de pavimento, laminado adesivo sensivel á pressáo para fixar um marcador de pavimento para uma superficie de rodovia, marcador suspenso de pavimento, e, processo de marcaçao de um pavimento apresentando uma superficie de rodovia com uma temperatura abaixo de 15°c
ECSP003836A (es) Composicion estable para dosis oral de liberacion extendida
BR9904742A (pt) Patch, conjunto constituìdo por um patch e por um recipiente, e processo
BR9703489A (pt) Composição aquosa e de tinta de tráfego de cura rápida estável no armazenamento processo para reduzirão tempo de secagem-não-captação de uma indicação de tráfego sobre uma superfície de rodovia e indicação de tráfego sobre um superfície de rodovia
ES2037522T3 (es) Nuevo dispositivo de cierre para manguitos contractiles.
ES2118249T3 (es) Parche que contiene dexpanthenol para la aplicacion percutanea de hormonas esteroideas.
ES2149927T3 (es) Metodo para interconectar un dispositivo electronico utilizando un medio portador de soldadura, retirable.
DK1355636T3 (da) Transdermalt terapeutisk system til administrering af carboxylgruppeholdige, ikke-steroidale antiflogistika samt en fremgangsmåde til fremstilling deraf
BR9810043A (pt) Dispositivo para a liberação controlada e/ou alterada de substáncias pesticidas contidas em composições sólidas ou em gel para suprimento a uma planta, e, processo para o tratamento de um vegetal com um pesticida
BR0205329A (pt) Composição lìquida formadora de pelìcula
DK1140039T3 (da) Transparente indretninger til perkutan nikotinadministration
EP1013734A4 (en) GELELY PRESSURE SENSITIVE ADHESIVE, ADHESIVE AND MEDICAL TACKY COMPOSITION WHICH CONTAINS THIS
BR0215366A (pt) Formulações transdérmicas adesivas de diclofenac sódico
FR2831879B1 (fr) Dispositif d&#39;individualisation de flans en materiau flexible en forme de disque
ES2095689T3 (es) Pelicula autoadhesiva de recubrimiento para el envasado de componentes electronicos.
BR9911960A (pt) Composição medicamentosa autoadesiva, e utilização da mesma
BRPI0405249A (pt) aperfeiçoamentos em rótulo e no método de obtenção de rótulo
PT1218203E (pt) Suporte de marcacao adesivo passivel de ser reposicionado e compativel com a pele
BR9402873A (pt) Sistema e processo para aplicar um material adesivo/coesivo a uma superfície de um objeto
DK228590D0 (da) Produkter, hvorpaa der er permanente tegn, og fremgangsmaade til deres fremstilling
BR9904659A (pt) Cartao plastico com monograma indelevel, somente revelavel se refletido mediante exposição a luz

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/70, A61K 31/381, A61P 25/16

Ipc: A61K 9/70 (2009.01), A61K 31/381 (2009.01), A61P 2

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM ART. 13 DA LPI ) NAO ESTA DE ACORDO COM O ARTIGO 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: LTS LOHMANN THERAPIE-SYSTEME AG (DE) , SCHWARZ PHA

B25D Requested change of name of applicant approved

Owner name: LTS LOHMANN THERAPIE-SYSTEME AG (DE) , UCB MANUFAC

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/03/2019